Loading patent…
AssigneeBaker Norton Pharmaceuticals, Inc.
InventorsSamuel Broder, Kenneth L. Duchin, Sami Salim
Estimating the term…
A method of increasing the bioavailability upon oral administration of a pharmacologically active target agent, particularly an antitumor or antineoplastic agent which exhibits poor or inconsistent oral bioavailability (e.g., paclitaxel, docetaxel or etoposide), comprises the oral co-administration to a mammalian patient of the target agent and an oral bioavailability-enhancing agent (e.g., cyclosporin A, cyclosporin D, cyclosporin F or ketoconazole). The enhancing agent may be administered orally from 0.5-24 hrs. prior to the oral administration of one or more doses of the target agent, substantially simultaneously with the target agent or both prior to and substantially simultaneously with the target agent. A method of treating mammalian patients suffering from diseases responsive to target agents with poor oral bioavailability, as well as oral dosage forms containing such target agents, combination oral dosage forms containing bioavailability-enhancing agents and target agents and kits containing enhancing and target agent dosage forms and dosing information for the co-administration of the same are also disclosed.
A method of increasing the bioavailability upon oral administration to a human patient of a taxane, comprising orally co-administering to the human patient a taxane and an oral bioavailability-enhancing agent comprising a p-glycoprotein inhibitor, wherein the oral bioavailability enhancing agent is administered substantially simultaneously with administration of the taxane, prior to administration of the taxane, or both prior to and substantially simultaneously with administration of the taxane.
A method of increasing the bioavailability upon oral administration to a human patient of paclitaxel, comprising orally co-administering to the human patient paclitaxel and an oral bioavailability-enhancing agent comprising a p-glycoprotein inhibitor, wherein the oral bioavailability enhancing agent is administered substantially simultaneously with administration of paclitaxel, prior to administration of paclitaxel, or both prior to and substantially simultaneously with administration of paclitaxel.
A method of increasing the bioavailability upon oral administration to a human patient of docetaxel, comprising orally co-administering to the human patient docetaxel and an oral bioavailability-enhancing agent comprising a p-glycoprotein inhibitor, wherein the oral bioavailability enhancing agent is administered substantially simultaneously with administration of docetaxel, prior to administration of docetaxel, or both prior to and substantially simultaneously with administration of docetaxel.
A method of treating a human afflicted with a disease responsive to a taxane, comprising orally co-administering to the human a taxane and an oral bioavailability-enhancing agent comprising a p-glycoprotein inhibitor.
A method of treating a human afflicted with a disease responsive to paclitaxel, comprising orally co-administering to the human paclitaxel and an oral bioavailability-enhancing agent comprising a p-glycoprotein inhibitor.
A method of treating a human afflicted with a disease responsive to docetaxel, comprising orally co-administering to the human docetaxel and an oral bioavailability-enhancing agent comprising a p-glycoprotein inhibitor.
An oral pharmaceutical dosage form comprising a taxane which is paclitaxel or docetaxel, and an oral bioavailability-enhancing agent comprising a p-glycoprotein inhibitor.
A kit comprising an oral dosage form containing an oral bioavailability enhancing agent comprising a p-glycoprotein inhibitor, and an oral dosage form containing a taxane which is paclitaxel or docetaxel, or a combination oral dosage form containing both the enhancing agent and the taxane.
Dependencies are inferred from the claim text.